IMU Biosciences has closed its Series A at over $53m (£40m) in an oversubscribed financing round co-led by IQ Capital and Molten Ventures.
IMU is decoding the immune system to pioneer a shift in how diseases are understood and diagnosed. The firm uses a blood sample to measure over 100 million immune data points, creating a detailed immune picture.
With its data, the company is establishing a universal standard for immune profiling which will enable the discovery of new immune mechanisms and identify precision approaches, monitor disease progression and the course of treatment, and predict treatment suitability and efficacy for patients.
The funding, which was also supported by the British Business Bank, Meltwind and existing investors, will be used to support the company’s operational expansion and clinical platform and infrastructure development.
Investment will also be used to advance IMU’s clinical programmes, including its stem cell transplant and solid organ transplant programmes in addition to MANIFEST, a UK research consortium investigating patient response to cancer immunotherapies.
“Despite the immune system’s profound importance on all aspects of our health, the system as a whole remains poorly understood – obscured by tools that are fragmented, mechanistic and low-resolution,” says John Baker, CEO at IMU Biosciences.
“With the largest immune system dataset globally and proprietary technology, IMU is uniquely positioned to fuel discoveries, devise treatments and empower clinicians, improving outcomes for patients across the full spectrum of human health and disease.”
